Maxicold is a combination drug used for the symptomatic treatment of acute respiratory diseases.
Release form and composition
Maxicold is available in the following dosage forms:
- Powder for preparation of solution for intake: crystalline, with a specific smell, white crystals and easily disintegrating lumps are allowed, light yellow (with a characteristic orange or lemon smell) or pink (with a characteristic raspberry smell) color; the prepared solution is opalescent, has a light yellow or pink color (5 g each in bags of composite material, 5, 10 or 50 bags in a carton box);
- Tablets, film coated: biconvex, oval, with risky, pinkish-orange color; on the cross-section of pinkish-orange color, with orange and white interspersions (2, 10 or 12 each in blisters, 1 or 2 packs in a cardboard box).
The composition of 1 bag contains active ingredients:
- Ascorbic acid - 60 mg;
- Paracetamol - 750 mg;
- Phenylephrine hydrochloride - 10 mg.
Auxiliary components: colloidal silicon dioxide, saccharin sodium, citric acid, sodium citrate, lactose, flavoring, potato starch, dye quinoline yellow (orange or lemon Maxicold) or acid red (raspberry Maxicold).
The composition of 1 tablet contains the active substances:
- Paracetamol - 500 mg;
- Phenylephrine hydrochloride - 10 mg;
- Ascorbic acid - 30 mg.
- Nucleus: croscarmellose sodium, calcium phosphate, ethyl cellulose, hydroxypropyl cellulose (giproloza), talc, magnesium silicate, dye sun-sunset yellow;
- Shell: giproloza, hypromellose, talc, titanium dioxide, sunset dye yellow sunset.
Indications for use
Maxicold is prescribed for the symptomatic treatment of infectious and inflammatory diseases (including influenza and other acute respiratory viral infections (ARVI)), which are accompanied by chills, fever, headache, nasal congestion, pain in muscles, bones, sinuses and throat.
- Pronounced disorders of the kidneys and liver;
- Thyrotoxicosis (hyperthyroidism);
- Heart disease (marked stenosis of the aortic orifice);
- Angle-closure glaucoma;
- Arterial hypertension;
- Acute myocardial infarction;
- Prostate hyperplasia;
- Simultaneous administration with tricyclic antidepressants, beta-blockers, monoamine oxidase inhibitors (including a period of up to 14 days after their cancellation);
- Simultaneous use with other medicines containing paracetamol and drugs to relieve symptoms of flu, cold and nasal congestion;
- Age up to 12 years (for Maxicold in powder form) and up to 9 years old with a body weight less than 30 kg (for Maxicold in the form of tablets);
- Hypersensitivity to the drug.
Maxicold should be taken cautiously with lactating and pregnant women, elderly patients, as well as with benign hyperbilirubinemia and the genetic absence of glucose-6-phosphate dehydrogenase.
Additionally, when taking Maxicold in the form of a powder for the preparation of a solution for ingestion, caution should be exercised in patients with hepatic or renal insufficiency, diabetes mellitus and a hereditary glucose absorption disorder.
Dosing and Administration
Before using the contents of 1 sachet need to fill with hot water and stir until dissolved. The solution is taken hot.
The drug is prescribed 1 sachet up to 4 times a day, observing the interval from 4 to 6 hours (you should not take the drug with an interval of less than 4 hours).
Children from 12 years old are prescribed 1 sachet every 6 hours (no more than 3 sachets per day).
Tablets are taken orally, squeezed with plenty of liquid, before meals or 1-2 hours after a meal. The regimen is determined by age:
- Adults and children from 12 years old (weighing more than 40 kg): every 4-6 hours, 1-2 tablets;
- Children 9-12 years old (weighing more than 30 kg): every 4-6 hours, 1 tablet.
Reception frequency - no more than 4 times a day with an interval of at least 4 hours.
Exceeding the indicated dose is not recommended.
Without a consultation with a doctor as a pain reliever, Maxicold should not be taken for longer than five days, and as a febrifuge for three days.
If symptoms persist, it is recommended to consult a doctor.
During therapy may develop side effects due to the action of active substances:
- Paracetamol: allergic reactions (urticaria, skin rash, angioedema); rarely - leukopenia, thrombocytopenia, agranulocytosis;
- Phenylephrine: headache, nausea, slight increase in blood pressure; rarely - heartbeat (pass after the cancellation of Maxicold)
With long-term use of Maxicold in doses that are much higher than recommended, there may be an increased risk of impaired renal and liver function.
Patients taking anticoagulants (warfarin), domperidone, metoclopramide, kolestiramin need to use Maxicold is determined by the doctor individually.
To avoid toxic damage to the liver during therapy, drinking alcohol is not recommended. Also, Maxicold should not be prescribed to patients with chronic alcoholism.
The drug may distort the results of laboratory tests that assess the concentration of uric acid and glucose in plasma.
When using the drug for more than 5-7 days, it is necessary to monitor the functional state of the liver and peripheral blood counts.
The question of the expediency of the appointment of Maxicold to pregnant women is decided by the doctor individually.
With the simultaneous use of Maxicold with some drugs, undesirable effects may occur:
- Sedatives, monoamine oxidase inhibitors, ethanol: enhancing their effects;
- Ethanol, hepatotoxic drugs, inducers of enzymes of microsomal oxidation in the liver (barbiturates, phenytoin, phenylbutazone, rifampicin, tricyclic antidepressants, etc.): an increased risk of the development of the hepatotoxic effect of paracetamol;
- Anticoagulants: increase their effect when using high doses of paracetamol;
- Uricosuric drugs: a decrease in their effectiveness;
- Barbiturates (with long-term use): a decrease in the effectiveness of paracetamol;
- Domperidone and metoclopramide: increase the speed of absorption of paracetamol;
- Kolestiramin: decrease in the rate of absorption of paracetamol;
- Inhibitors of microsomal oxidation enzymes (including cimetidine): reducing the risk of the hepatotoxic effect of paracetamol;
- Ethanol: possible development of acute pancreatitis;
- Nonsteroidal anti-inflammatory drugs: increased risk of developing analgesic nephropathy and renal papillary necrosis, the onset of end-stage renal failure (with long-term use of paracetamol);
- Salicylates: increased risk of developing bladder or kidney cancer (with prolonged use of high doses of paracetamol);
- Diflunisal: an increase in the plasma concentration of paracetamol and the risk of developing hepatotoxicity;
- Myelotoxic drugs: increased paracetamol hematotoxicity;
- Diuretics and antihypertensive drugs (including methyldopa, mecamylamine, guanadrel, guanethidine): reduced hypotensive effect;
- Nitrates: reduced antianginal effect;
- Alpha-blockers (phentolamine), phenothiazines, furosemide and other diuretics: reduction of the hypertensive effect of pheniramine;
- Monoamine oxidase inhibitors (including procarbazine, furazolidone, selegilin), ergot alkaloids, oxytocin, methylphenidate, tricyclic antidepressants, adrenostimulants: increased vasoconstrictive effect and phenylephrine arrhythmogenicity;
- Reserpine: possible development of arterial hypertension;
- Ergotamine, ergometrine, oxytocin, methylergometrine, doxapram: an increase in the severity of the vasoconstrictor effect of pheniramine;
- Inhalation anesthetics (including enflurane, chloroform, isoflurane, halothane, methoxyflurane): an increased risk of severe atrial and ventricular arrhythmias;
- Thyroid hormones: an increase in the effect of phenylephrine and the associated risk of coronary insufficiency (especially with coronary atherosclerosis);
- Tetracyclines and benzylpenicillin: increasing their concentration in the blood;
- Heparin and indirect anticoagulants: a decrease in their effectiveness;
- Ethanol: an increase in total clearance, which in turn lowers the concentration of ascorbic acid in the body;
- Antipsychotic drugs (neuroleptics): reduced therapeutic effect;
- Acetylsalicylic acid: increased excretion of ascorbic acid in the urine and a decrease in acetylsalicylic acid excretion;
- Oral contraceptives, acetylsalicylic acid, alkaline drink and fresh juices: a decrease in the absorption and absorption of ascorbic acid;
- Iron preparations: improvement of their absorption in the intestine;
- Short-acting salicylates and sulfonamides: increased risk of crystalluria;
- Alkaline drugs (including alkaloids): an increase in their elimination;
- Oral contraceptives: a decrease in their concentration in the blood;
- Salicylates, calcium chloride, quinoline drugs, glucocorticoids with prolonged use: depletion of ascorbic acid reserves;
- Primidone and barbiturates: increased excretion of ascorbic acid in the urine.
Terms and conditions of storage
Store in a dry place out of reach of children at a temperature up to 25 ° C.
Shelf life - 2 years.